United Therapeutics Corp. SEC Filings

Judy D. Olian, a director of United Therapeutics Corporation (UTHR), reported the sale of 1,800 shares of the issuer's common stock on 09/19/2025 at a weighted-average price of $415.4266 per share. After the reported disposition, the reporting person beneficially owned 5,045 shares. The Form 4 lists the transaction code as S (sale) and notes the trades executed at prices ranging from $415.29 to $415.55, with the weighted-average price disclosed above. The filing is signed under power of attorney by John S. Hess, Jr.

UNITED THERAPEUTICS (UTHR) Form 144 summary: A holder intends to sell 1,800 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate aggregate market value of $747,767.70. The shares were acquired on 07/13/2024 as restricted stock from the issuer and were fully paid on that date. The filing lists an approximate total outstanding share count of 45,226,262 and an approximate sale date of 09/19/2025. No securities were reported sold by the same person in the past three months. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

United Therapeutics insider transaction: Paul A. Mahon, Executive Vice President & General Counsel, exercised 11,000 stock options with an exercise price of $135.42 on 09/18/2025 under a plan established 12/24/2024. Immediately following the exercise, the reporting person sold the 11,000 resulting shares in multiple block trades executed the same day at weighted average prices ranging from about $403.76 to $408.43, with the individual reported weighted prices shown between $402.50 and $408.1142.

After these transactions the reporting person beneficially owns 36,781 shares of common stock and retains derivative exposure to 55,000 shares underlying options. The filing states the exercise and sales were made pursuant to a pre-arranged 10b5-1 plan entered into on December 24, 2024, and includes price ranges and weighted-average reporting for the multiple trades.

United Therapeutics insider transactions: Martine A. Rothblatt, Chairperson & CEO of UNITED THERAPEUTICS (UTHR), exercised stock options and sold common stock on 09/17/2025 and 09/18/2025 under a pre-arranged 10b5-1 plan entered May 2, 2025. On each date she exercised 4,000 options at a $120.26 exercise price, receiving 4,000 shares per exercise. Those exercises were followed by sales of the resulting shares in multiple trades at weighted-average prices around $399.97, $400.90, $403.27, $405.20 and $406.04 as reported. The filing discloses substantial indirect ownership through spouse and family trusts and notes the 10b5-1 plan will continue until exhaustion of a tranche of 294,000 options expiring March 15, 2026, or December 31, 2025, whichever is earlier.

Form 144 notice by an insider to sell 11,000 shares of Common stock via Morgan Stanley on 09/18/2025. The shares were acquired through a stock option exercise on 09/18/2025 and paid for in cash. The filing lists an aggregate market value of $4,467,907.40 for the 11,000 shares and shows 45,226,262 shares outstanding for the class. The filing also discloses six prior sales by the same person during the past three months, each for 11,000 shares between 06/26/2025 and 09/04/2025, with gross proceeds shown for each sale.

United Therapeutics insider Martine Rothblatt notified a proposed sale under Rule 144 of 4,000 common shares to be executed through TD Securities on 09/18/2025 on NASDAQ with an aggregate market value of $1,617,665.13. The filing shows the shares were originally acquired on 03/15/2016 as executive deferred compensation (294,000 shares) and paid via common shares. The filing also lists prior sales by the same person over the past three months totaling 32,000 common shares on dates between 09/09/2025 and 09/17/2025 with detailed gross proceeds for each sale. The issuer’s outstanding common shares are reported as 45,230,000.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported option exercises and sales under a pre-arranged 10b5-1 plan. On 09/16/2025 she exercised 4,000 stock options with a $120.26 exercise price and acquired 4,000 shares. Concurrently she sold 1,000 shares at a weighted average price of $399.281 and 3,000 shares at a weighted average price of $400.5937, reducing her direct holdings to 130 shares while retaining substantial indirect holdings through trusts and spouse (total indirect holdings listed: 324,518; 258,117; 45,596; 15,962). The 10b5-1 plan was established May 2, 2025 and covers a tranche of 294,000 options expiring March 15, 2026 or until December 31, 2025.

UNITED THERAPEUTICS (UTHR) Form 144 notice reports a proposed sale of 4,000 common shares through TD Securities (USA) LLC on 09/17/2025, with an aggregate market value of $1,600,686.85. The securities were originally acquired on 03/15/2016 as part of an executive deferred compensation arrangement from Martine Rothblatt, totaling 294,000 shares acquired on that date and paid via vested options settled in common shares. The filing lists the company’s outstanding shares as 45,230,000.

The notice also discloses six sales by Martine Rothblatt during 09/09–09/16/2025 totaling 28,000 shares with gross proceeds shown for each sale. The filer represents they are not aware of undisclosed material adverse information and certifies compliance with Rule 144 procedures.

Michael Benkowitz, President and COO of United Therapeutics (UTHR), reported multiple transactions dated 09/15/2025 involving the exercise of stock options and subsequent sales of resulting common shares held in trusts. The filing shows the exercise of 14,625 options at a $135.42 exercise price and 7,875 options at a $146.03 exercise price, converting into shares held in trusts for which the reporting person is a beneficiary or has sole investment and voting power.

The sold shares were executed under a Rule 10b5-1 trading plan established on June 3, 2025, and were sold in multiple trades at weighted average prices reported between approximately $396.44 and $403.51 per share (ranges disclosed per trade group). The Form 4 discloses the trust arrangements and that transactions were effected in multiple trades with weighted-average prices disclosed in explanatory footnotes.